Search

Displaying results 4561 - 4570 of 7059 in total
  1. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.

  2. Drug

    Dimethylthiambutene

    go.drugbank.com/drugs/DB01444
    ExperimentalIllicit

    Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug.

    Synonyms: 3-dimethylamino-1,1-di-(2'-thienyl)-1-butene, N,N,1-trimethyl-3,3-di-2-thienylallylamine
  3. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.

    Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  4. Drug

    GS-100

    go.drugbank.com/drugs/DB18337
    Investigational

    GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence

  5. Drug

    Imalumab

    go.drugbank.com/drugs/DB15558
    Investigational

    Imalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).

  6. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  7. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals. … PW2101 is a beta blocker intended for the treatment of hypertension and angina.

  8. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    Sensitivity to geraniol may be identified with a clinical patch test. … Geraniol has demonstrated a wide spectrum of pharmacological activities including antimicrobial, anti-inflammatory, antioxidant, anti-cancer, and neuroprotective to name a few [A34260,A34261,A34262].

  10. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF